Braschi A, Scherini A, Carbonera D, Mapelli A, Bellinzona G, Bobbio Pallavicini F, Dionigi R, Gasperi A
Minerva Anestesiol. 1979 Nov;45(11):871-81.
Some recent views on pathophisyology of "myasthenia gravis" are presented. The Authors explain the typical damage of myasthenia gravis, i.e. the progressively reduced muscolar function on the basis of an autoimmune derangement affecting the motor-end plates. The most commonly used types of treatment, both medical (i.e. antiChE, A.C.T.H., steroids and immunodepressant drugs) and surgical (thymectomy) are reviewed. The very important role of Intensive Care for the treatment either of myasthenia gravis "per se" or of possible consequences of some drugs (A.C.T.H. steroids) is also stressed. Finally the Authors present their results about their experience on 36 patients affected by myasthenia gravis and admitted to I.C.U. once (29 patients) or twice or more (7 patients). The Authors describe some practical problems presented by patients during their stay in I.C.U.
本文介绍了一些关于“重症肌无力”病理生理学的最新观点。作者基于影响运动终板的自身免疫紊乱,解释了重症肌无力的典型损害,即肌肉功能逐渐减退。本文回顾了最常用的治疗方法,包括药物治疗(如抗胆碱酯酶药、促肾上腺皮质激素、类固醇和免疫抑制药物)和手术治疗(胸腺切除术)。还强调了重症监护在治疗重症肌无力“本身”或某些药物(促肾上腺皮质激素、类固醇)可能产生的后果方面的重要作用。最后,作者介绍了他们对36例重症肌无力患者的经验结果,这些患者曾入住重症监护病房一次(29例)或两次及以上(7例)。作者描述了患者在重症监护病房住院期间出现的一些实际问题。